metaPreg - Methotrexate (Pre-conception only) during pregnancy

Methotrexate (Pre-conception only)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.41 [0.59, 3.38]	0%	5 studies	27,659	214	not evaluable	ROB	-
Major congenital malformations	1.24 [0.45, 3.42]	0%	3 studies	27,658	210	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Small for gestational age (weight)	0.82 [0.27, 2.47]	0%	2 studies	6	45	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	0.55 [0.18, 1.70]	73%	3 studies	138	274	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks)	1.74 [0.27, 11.38]	22%	3 studies	6	274	not evaluable	ROB	-
Therapeutic terminations of pregnancy	1.42 [0.51, 3.97]	0%	3 studies	22	274	not evaluable	ROB	-
Elective/induced termination of pregnancy	2.40 [1.06, 5.42]	-	1 study	62	136	not evaluable	ROB	4.23 [1.32; .]
Intrauterine deaths (as a whole or unspecified)	0.37 [0.09, 1.53]	74%	2 studies	57	138	not evaluable	ROB	-